Phosphocholine

Phosphocholine

SCHEMBL14738989

C=C(C)C(=O)OCCO.C[N+](C)(C)CCOP(=O)([O-])O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 2/20 0.41
CHRM5 P08912 4/20 0.40
CHRM1 P11229 4/20 0.40
CHRM3 P20309 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
CHRM2 P08172 3/20 0.38
CHRM4 P08173 3/20 0.38
HTR1A P08908 2/20 0.38
CHRNB2 P17787 2/20 0.38
CHRNA7 P36544 2/20 0.38
CHRNA4 P43681 2/20 0.38
PGR P06401 1/20 0.38
TBXA2R P21731 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
CHRNA10 Q9GZZ6 1/20 0.38
CHRNA9 Q9UGM1 1/20 0.38
THRB P10828 1/20 0.37
MAPT P10636 2/20 0.37
BLM P54132 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphocholine SCHEMBL15862263 0.89 CHRM5 (0.42) GALR3CHRM5CHRM1CHRM3SMN1; SMN2
Phosphocholine SCHEMBL28232275 0.89 CHRM5 (0.42) GALR3CHRM5CHRM1CHRM3SMN1; SMN2
Phosphocholine SCHEMBL12979922 0.88 SMN1; SMN2 (0.45) CHRM5CHRM1CHRM3SMN1; SMN2CHRM2
Phosphocholine SCHEMBL1949342 0.86 TSHR (0.51) SMN1; SMN2THRBMAPTTSHRLMNA
SCHEMBL6462016 0.84 THRB (0.45) GALR3CHRM5CHRM1CHRM3SMN1; SMN2
SCHEMBL24982077 0.84 THRB (0.40) GALR3CHRM5CHRM1CHRM3SMN1; SMN2
Phosphoric Acid SCHEMBL9619842 0.84 CHRM5 (0.53) GALR3CHRM5CHRM1CHRM3SMN1; SMN2
Phosphocholine SCHEMBL2456735 0.82 SMN1; SMN2 (0.42) GALR3CHRM5CHRM1CHRM3SMN1; SMN2
Phosphoric Acid SCHEMBL7192564 0.82 CHRM5 (0.55) GALR3CHRM5CHRM1CHRM3SMN1; SMN2
SCHEMBL20401677 0.81 SMN1; SMN2 (0.49) GALR3CHRM5CHRM1CHRM3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180105665-A1 SURFACE MODIFIED POLYMER COMPOSITIONS LUBRIZOL ADVANCED MATERIALS, INC. 2018-04-19 US claimed
US-11578205-B2 Antimicrobial, non-thrombogenic polymer composition LUBRIZOL ADVANCED MATERIALS, INC. (US) 2023-02-14 US disclosed
EP-3207128-B1 BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES KODIAK SCIENCES INC (US) 2022-07-27 EP disclosed
CN-107787230-B Surface-modified polymer composition 路博润先进材料公司 2022-01-21 CN disclosed
EP-3361868-B1 BIOCIDALLY ACTIVE POLYMER COMPOSITIONS LUBRIZOL ADVANCED MAT INC (US) 2021-12-15 EP disclosed
US-20210277231-A1 Antimicrobial, Non-Thrombogenic Polymer Composition LUBRIZOL ADVANCED MAT INC (US) 2021-09-09 US disclosed
US-11071771-B2 Butyrylcholinesterase zwitterionic polymer conjugates KODIAK SCIENCES INC. (US) 2021-07-27 US disclosed
US-10829606-B2 Surface modified polymer compositions LUBRIZOL ADVANCED MATERIALS, INC. 2020-11-10 US disclosed
US-10827757-B2 Biocidally active polymer compositions LUBRIZOL ADVANCED MATERIALS, INC. 2020-11-10 US disclosed
US-20190255155-A1 BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES OLIGASIS, LLC 2019-08-22 US disclosed
WO-2017066242-A1 BIOCIDALLY ACTIVE POLYMER COMPOSITIONS LUBRIZOL ADVANCED MATERIALS, INC. (US) 2017-04-20 WO disclosed
WO-2016172460-A1 SURFACE MODIFIED POLYMER COMPOSITIONS LUBRIZOL ADVANCED MATERIALS, INC. (US) 2016-10-27 WO disclosed
US-20160184445-A1 BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES OLIGASIS, LLC 2016-06-30 US disclosed
WO-2016061562-A2 BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES KODIAK SCIENCES INC. (US) 2016-04-21 WO disclosed
US-9006305-B2 Biocompatible material VERTELLUS SPECIALTIES INC. (US) 2015-04-14 US disclosed
US-8980956-B2 Methods for producing biocompatible materials VERTELLUS SPECIALITIES INC. (US) 2015-03-17 US disclosed
EP-2751153-A1 METHODS FOR PRODUCING BIOCOMPATIBLE MATERIALS Vertellus Specialties Inc. (US) 2014-07-09 EP disclosed
WO-2013033553-A1 METHODS FOR PRODUCING BIOCOMPATIBLE MATERIALS VERTELLUS SPECIALTIES INC. (US) 2013-03-07 WO disclosed
US-20130059926-A1 METHODS FOR PRODUCING BIOCOMPATIBLE MATERIALS VERTELLUS HOLDINGS, LLC 2013-03-07 US disclosed
US-20130059970-A1 BIOCOMPATIBLE MATERIAL VERTELLUS HOLDINGS, LLC 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160184445-A1 BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES BCHE, ACHE, FCER2 GALR3 1277/4885CHRM5 250/4885CHRM1 411/4885
US-11071771-B2 Butyrylcholinesterase zwitterionic polymer conjugates BCHE, ACHE, FCER2 GALR3 1277/4885CHRM5 250/4885CHRM1 411/4885
US-20130059970-A1 BIOCOMPATIBLE MATERIAL VCL, ITGAM, MACF1 GALR3 3997/4885CHRM5 3319/4885CHRM1 1372/4885
US-20190255155-A1 BUTYRYLCHOLINESTERASE ZWITTERIONIC POLYMER CONJUGATES BCHE, ACHE, FCER2 GALR3 1277/4885CHRM5 250/4885CHRM1 411/4885
US-10827757-B2 Biocidally active polymer compositions PUF60, FGB, PARG GALR3 2892/4885CHRM5 4779/4885CHRM1 4755/4885
US-20130059926-A1 METHODS FOR PRODUCING BIOCOMPATIBLE MATERIALS VCL, ECPAS, MACF1 GALR3 3817/4885CHRM5 1752/4885CHRM1 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.